A systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what's on the label what's in the product?

Objectives: To review the literature regarding label accuracy and contamination of medical cannabinoid-based products. Methods: A systematic review with meta-analysis following PRISMA guidelines. This study is registered with PROSPERO (CRD42019131565). Results: Five studies reported label accuracy data ranging between 17% and 86%. Four studies reported contaminants, including pesticides, solvents and AB-FUBINACA. Meta-analysis was limited to the proportion of pesticide-contaminated samples found in two studies (0.25 (95% CI [0.10, 0.40])) and displayed significant heterogeneity. Conclusions: Label inaccuracies and contaminants are found across a spectrum of cannabinoid-based products. The review highlights the paucity and heterogeneity of research relating to cannabinoid-based products in light of changing global legislation. Further robust research is required to support ongoing pharmacovigilance and patient safety.

Automated summary

Label inaccuracies and contaminants are common in medical cannabinoid-based products, highlighting the lack of research data on these products. Further robust research is needed to support ongoing pharmacovigilance and patient safety.